Dallas’ Meeting Protocol Worldwide Appoints New Chief Executive Officer

Paige Bingham will succeed Pat Bingham, the company's founder, and previous CEO, who is retiring after many years of leadership.

Paige Bingham has been appointed chief executive officer of Dallas-based Meeting Protocol Worldwide, a family of life science brands that provide services to the pharmaceutical and biotechnology industries.

Paige Bingham will succeed Pat Bingham, the company’s founder, and previous CEO, who is retiring after many years of leadership.

“I am honored to lead Meeting Protocol Worldwide into its next phase of growth,” Paige Bingham said in a statement. “We have a long-standing commitment to excellence and innovation. I am dedicated to building on the company’s strong foundation and reputation, including growing our technology and services within Scout Clinical and Atlas Clinical Academy. I look forward to honoring Pat’s legacy of relentless customer service and creating order out of chaos.”

Paige Bingham brings a strong reputation and a wealth of global pharmaceutical meeting planning experience with a proven track record of customer success to her new role.

Pat Bingham said in a statement, “After years of dedicated service, I am delighted to be succeeded by Paige, who has been an integral part of our success in the company’s significant expansion with our Scout Clinical and Atlas Clinical Academy divisions. Her strategic vision, industry knowledge, and unwavering commitment make her the ideal candidate to lead the company.”

Paige Bingham joined Meeting Protocol Worldwide in 1999 and played a key role in the company’s growth and expansion into numerous countries by establishing the London office and growing the European market.

After many years abroad, she returned to the Dallas headquarters, at which time she was appointed chief operating officer, bringing with her a strong belief in cultural diversity and inclusivity, the company said.

As COO, Paige was instrumental in the creation of Scout Clinical, a market-leading patient reimbursement and concierge division. She has driven adoption of Scout Clinical into some of the Top 10 global pharmaceutical and contract research organizations.

The company said she also oversaw the development of Atlas Clinical Academy, the company’s LMS technology platform.

Meeting Protocol Worldwide is a family of brands providing full-service meeting planning for the pharmaceutical and biotechnology industries as well as clinical trial patient concierge travel and reimbursement services.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • "There are over 10,000 rare diseases that affect millions of people worldwide, and most of them are genetic," notes UT Southwestern's Steven Gray (above, with Susan Iannaccone, M.D.). Testing on a total of eight genetic diseases has been approved for funding by the Bespoke Gene Therapy Consortium and other organizations.

  • Formerly AllerVie’s chief medical officer, Dr. Weily Soong will lead efforts to drive innovation with new therapies and diagnostics for asthma, allergies, and other related immunological conditions at AllerVie Clinical Research.

  • Dallas-based enterprise browser unicorn Island has added Keith Weatherford to its executive team as vice president of worldwide channel sales. Island emerged from stealth in February 2022. Valued at $1.3 billion in March, the startup continues to attract big investments for its enterprise browser, which aims to protect companies' SaaS tools and internal web apps from data leaks with a long list of security features. Weatherford brings more than 20 years of experience developing and implementing channel partner strategies for leading security companies, Island said. He'll be tasked with building and scaling Island’s global channel presence. Island CEO and co-founder…

  • Dallas' Secretome Therapeutics Appoints Board Director, Assembles Clinical Advisory Board

    Secretome Therapeutics, a Dallas-based biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells, has appointed Margot Connor to its board of directors and announced the appointment of its clinical advisory board composed of world-class clinicians and researchers in the field of heart failure. “I have been fortunate to be part of the stem cell-based therapy evolution, and I believe secretomes are a true breakthrough in this extraordinary field,” Connor said in a statement. “Secretome Therapeutics’ team, vision, and groundbreaking products have the potential to revolutionize treatment for a wide range of chronic, inflammatory diseases, and I am thrilled to…

  • Downtown Dallas Inc. announced that Katy Murray is the 2023 chair of the board for the 65-year-old nonprofit. "It is an honor to assume this position at a time of historic growth for downtown," Murray said in a statement. "For 65 years, DDI has served as the lead advocate for a vibrant, safe, and clean Downtown, a Downtown that is both a place to work and a place to live. DallasNews Corp. is proud of our nearly 140-year commitment to Downtown and there is no stronger advocacy group for our urban core than DDI." Murray, the president and chief financial…